Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Barinthus Biotherapeutics plc.BRNS · Entity 9597 | Chief Scientific Officer | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Barinthus Biotherapeutics plc.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2034-01-02 | Direct | 105,000 |
Reported balance
After 2024-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 105,000 · Balance 105,000 F1: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 13:56 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001104659-24-001167 · tm241766-4_4seq1.xml · derivative · entry 1 Pelletier Nadege · CIK 0001965689 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 105,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 01, 2023 Filed Feb 24, 2023 22:25 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 485,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001104659-23-025391 · tm237643-6_4seq1.xml · derivative · entry 1 Pelletier Nadege · CIK 0001965689 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485,000 Underlying: Ordinary Shares · 485,000 shares Expires 2033-02-01 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 1, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.